Selecting Therapy for AML With Predictive Biomarkers or Actionable Alterations

Source: Acute Myeloid Leukemia: Reviewing Current Best Practice and Exploring Novel Paradigms Ahead
Download Slideset
Download these slides from a live symposium for the most recent data on selecting AML therapy for patients with predictive biomarkers or actionable alterations.
Eytan M. Stein, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 979 KB
Released: December 9, 2022

Acknowledgements

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
NCCN Logo
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Astellas
Daiichi Sankyo, Inc.
Gilead Sciences, Inc.
Servier Pharmaceuticals
Syndax Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings